Arcutis Biotherapeutics, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +95.3%
EBITDA: +114.9%
EBIT: +102.6%
EPS: +98.2%
Free cash flow: +123.1%
Operating cash flow: +124.3%

Forward estimates

Revenue: +37.3%
EBITDA: —
EPS: +3016.7%

Three-year CAGR

Revenue: +367.3%
EBITDA: +102.3%
EBIT: +90.5%
Net income: +88.5%
EPS: +88.8%
Free cash flow: +94.4%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.